Even in the midst of the COVID-19 pandemic, the medical community made advances throughout 2020. Here are 5 of the years most impactful innovations.
Overall, 2020 has been a tumultuous year. From a health perspective, its been one turned upside down with a deadly global pandemic reorienting how we live our lives and relate to others.
The COVID-19 pandemic has justifiably dominated headlines and attention from media, policymakers, and health officials alike.
While its clearly the defining public health, cultural, economic even political event of the year, the pandemic shouldnt obscure the fact that 2020 was also a time of great medical innovation.
From breakthroughs in oncology, gene therapies, and heart health, to the development of COVID-19 vaccines that are now being administered domestically and around the world, theres a lot that the medical community can be proud of in 2020.
Healthline touched base with leading experts about some of the most impactful medical advances of the year and how they hint at a more hopeful tomorrow.
Almost every expert Healthline interviewed agreed that gene editing was one of the big stories of the year.
In October, Emmanuelle Charpentier and Jennifer A. Doudna were awarded the Nobel Prize in Chemistry for discovering the CRISPR/Cas9 genetic scissors. (Just five other women have won this prize before).
This gene scissor tool is what it sounds like enzymes snip out pieces of DNA to restore them to their normal function, Dr. William Morris, executive medical director of Cleveland Clinic Innovations, told Healthline.
Charpentier and Doudna showed that these genetic tools could be controlled to cut any kind of DNA molecule at a designated location not just distinguish DNA from viruses, as these scissors exist in their natural form.
Essentially, it means we can rewrite the code of life, according to the Nobel Prizes official announcement.
Morris said that this innovation has wide-ranging ramifications for people who have a wide range of genetic conditions.
He cited sickle cell disease, a condition where malformed sickle-shaped red blood cells cause blockages in blood flow, preventing the protein hemoglobin from effectively ferrying needed oxygen through the body.
Morris said these microscopic tools can cut out these genetic errors.
There have only been a handful of drugs to treat these kinds of conditions in the past.
Now, this kind of development allows you to remove the error and replace the [genetic] code, kind of like in your computer or your iPhone if you downloaded a patch for new software to repair an app that always crashes thats what this is, Morris explained.
Its so earth-shatteringly amazing to tell these patients who otherwise faced an entire lifetime of pain and suffering. You can now use the word cure, which is unbelievable to think about, he said.
Olivier Elemento, PhD, director of the Englander Institute for Precision Medicine at Weill Cornell Medicine in New York City, told Healthline that 2020 is the year of the genetic code.
Were really able to use the genetic code in humans and viruses to help humanity in ways we were not equipped to before, in ways we couldnt do before, Elemento said.
He added that gene therapy in general, along with this CRISPR technology, is pretty extraordinary.
This more comprehensive understanding of genetics extends beyond the Nobel Prize.
For instance, Elemento said Weill Cornell Medicine, where he currently works, along with New York-Presbyterian Hospital and Illumina Inc. recently announced an initiative to sequence the genome of thousands of patients.
The more we understand about genetics and gene therapies, the more improved our precision medicine capacity will be opening up the possibilities of creating targeted therapies for all kinds of conditions.
Recently, the American Heart Association released its own list of innovations in medical treatments.
The spotlight includes a new phase 3 study that could change the way hypertrophic cardiomyopathy (when the heart muscle thickens and can stiffen) is treated.
It also highlights new treatments that might change up the first-line treatment for atrial fibrillation (AFib) a new minimally invasive surgery to prevent stroke and a new trial that reveals more treatment might not necessarily mean better treatment for coronary heart disease.
American Heart Association President Dr. Mitchell S.V. Elkind, MS, FAAN, FAHA, wrote in an email to Healthline that all of these advances over the past year reflect connections between seemingly disparate areas of medicine and the fact that we are most successful when we break down the barriers between fields.
In order to tackle an issue as wide ranging as heart disease, for instance, it takes an interdisciplinary, comprehensive approach.
For example, we learned more this year about the unexpected ways in which medicines designed to treat diabetes, the sodium glucose transporter 2 inhibitors, or SGLT2 inhibitors, help patients with heart failure, even those without diabetes, he added.
Elkind also cited our growing understanding of how connections between infectious diseases like the flu and COVID-19 are tied to greater risk for heart disease and stroke.
Often, the most important advances occur when experts from different areas work together in creative ways to solve a difficult problem, he wrote.
When asked if there was one particular heart health innovation that stood out the most to him, Elkind said that what resonated with him was something not tied to fancy medications or groundbreaking research.
An analysis of people from across the U.S. showed that rates of blood pressure control have begun to decline in the U.S., after almost two decades of better control. High blood pressure is one of the most important and easily treated risk factors for stroke and heart disease, and so this backsliding is especially alarming, he added.
He stressed that the study also pointed to the impact that having health insurance has on controlling ones blood pressure.
Those with some form of health insurance had blood pressure control rates of 4354 percent, while for those without insurance, it was only 24 percent, Elkind explained.
Improving access to quality care is one of the best ways we have to improve health, and that is where we at the American Heart Association will be placing our efforts in the coming years, he said.
Benjamin Neel, MD, PhD, director of the Perlmutter Cancer Center at NYU Langone Health, said 2020 has been a year thats seen cancer research push forward on multiple fronts.
He said technologies are in development for early detection of cancer by way of blood tests.
Its been known for quite some time that tumors release DNA into the blood stream, we have technology developing from the standpoint of monitoring tumors, conducting sensitive tests for tumors, for tests for recurrence of cancers and protein-based tests, Neel told Healthline, outlining current research.
He also cited technology that modulates the regulatory DNA sequence patterns which refers to the part of the DNA molecule that can change the way a gene expresses itself in a living thing to pinpoint when methylation patterns might point to the development of cancer.
Among other research highlights over the past year, Neel said researchers have been developing new ways of drugging genetic mutations.
He mentioned work being done in developing a compound to degrade the androgen receptor for prostate cancer cells what allows these cancer cells to grow.
One of the biggest changes this year came in the form of how our new normal work-from-home lifestyle has impacted medicine.
As more and more people stay away from offices and public spaces, theyre turning to telemedicine. The Zoom screen is the new doctors office.
Morris said that, while this isnt a medical discovery per se, its a crucial in some ways life-saving development for how we relate to healthcare in our lives.
Out of this whole pandemic, one of the things weve discovered as clinicians is that we need to see patients where they are and not force them to cross state lines, Morris said. While we had telemedicine, we had some patients over Skype and video visits, there were clear disincentives and policies in place against people easily crossing state lines to seek medical care, of receiving care remotely.
He said the pandemic facilitated a push at the government level and with state and federal regulators to reduce barriers to these tools that are critical lifelines for patients.
Even when healthcare professionals couldnt always see patients in person this year, the embrace of telemedicine has resulted in unprecedented increases in the adoption and use of these tools and seeking care, Morris added.
This pandemic has challenged us to question old perceptions and policies, so that was a very positive thing, he stressed.
Innovation doesnt necessarily have to be an aha moment in a lab or something right in front of us, he said. Its unfortunate we needed a pandemic or a challenge to sometimes see a barrier, and sometimes that barrier is us.
This year, a possible breakthrough in Alzheimers disease research and treatment came in the form of a blood test that can diagnose this progressive form of dementia.
While the news is huge, the test is still in the trial phase.
If ultimately approved, a simple test for the condition would be a game changer.
There are as many as 5 million people living with Alzheimers in the United States, a number that will likely triple by 2060, according to the Centers for Disease Control and Prevention (CDC).
While this test has yet to go through all the proper approvals, a company distributed the first publicly available Alzheimers blood test this fall.
As 2020 comes to a close, experts are looking to a more hopeful new year.
For its part, Cleveland Clinic, which enters its centennial next year, released a list of the predicted top 10 innovations of 2021.
Morris said that while many think of this year as fraught and divisive full of tragedy and setbacks looking back at these innovations shows theres always something to be grateful for and look forward to.
Elemento said that he expects a biotech and pharma boom in the next few years.
Citing the breakthroughs in gene therapies and genetic manipulation indicate what will be a continual embrace of this kind of medical technology.
All these technologies, now everyone knows they exist and that they can be used for good, it will be a big boom for these technologies, Elemento added.
Go here to see the original:
5 Medical Innovations You Probably Didn't Notice Happened in 2020 - Healthline
- A Year of DMD Gene Therapy Trial Failures - AJMC.com Managed Markets Network - November 3rd, 2024
- Hemophilia B: Gene Therapy Shows Promise - Medscape - November 3rd, 2024
- Around the Helix: Cell and Gene Therapy Company Updates October 30, 2024 - CGTLive - November 3rd, 2024
- 2024 PharmaVoice 100s: Cell and Gene Therapy Pioneers - PharmaVoice - November 3rd, 2024
- Cell therapy weekly: support for commercialization of complex therapies - RegMedNet - November 3rd, 2024
- Lexeo shares early data on Alzheimers gene therapy - Endpoints News - November 3rd, 2024
- Medicaid Aiming to Improve Patient Access to High-Cost Therapies - AJMC.com Managed Markets Network - November 3rd, 2024
- The Significance of Gene Therapy in Neuromuscular Medicine at the 2025 MDA Conference: Paul Melmeyer, MPP - Neurology Live - November 3rd, 2024
- OHSU researchers identify gene that could be key to future HIV vaccine - OHSU News - November 3rd, 2024
- Purespring gene therapy reduces kidney scarring in mice and is stably expressed in pigs - Fierce Biotech - November 3rd, 2024
- Data Roundup: October 2024 Features Update for TCR-Based Autologous Cell Therapy in Melanoma, the First Clinical Demonstration of Therapeutic RNA... - November 3rd, 2024
- NewBiologix Launches Xcell to Accelerate, Optimize, and Scale Gene and Cell Therapy Production - Business Wire - November 3rd, 2024
- Vertex Pharmaceuticals and CRISPR Therapeutics Casgevy: the 200 Best Inventions of 2024 - TIME - November 3rd, 2024
- Addressing gene and cell therapy commercialization challenges - TechTarget - November 3rd, 2024
- University of Pennsylvania gene therapy spinout Interius BioTherapeutics doses patient, achieves CAR therapy first - The Business Journals - November 3rd, 2024
- Roche will aim to tackle gene therapy challenges through Dyno deal - The Pharma Letter - November 3rd, 2024
- Behind the Breakthroughs: How to Turn $1,000,000 CAR Ts into Real Medicines - Inside Precision Medicine - November 3rd, 2024
- Terumo automates manufacturing to expand cell & gene therapies - European Pharmaceutical Manufacturer - November 3rd, 2024
- 12-Year-Old Leaves Washington DC Hospital As The First Patient To Receive Approved Gene Therapy For Sickle Cell Disease - AfroTech - November 3rd, 2024
- Lexeo Therapeutics Announces Positive Interim Data for - GlobeNewswire - November 3rd, 2024
- New FDA designations granted to NCATS for rare disease therapies. - NCBI - October 22nd, 2024
- $1.8 Million Awarded to Study the Durability of Gene Therapy - University of Arkansas Newswire - October 22nd, 2024
- By the numbers: US leads charge of cell and gene therapies - BioWorld Online - October 22nd, 2024
- University of Arkansas Researcher Awarded $1.8M for Gene Therapy Study - Arkansas Business - October 22nd, 2024
- Cellectis to Present Data on TALE-Base Editors and Non-Viral Gene Therapy at the ESGCT 31st Annual Congress - StockTitan - October 22nd, 2024
- Around the Helix: Cell and Gene Therapy Company Updates October 16, 2024 - CGTLive - October 22nd, 2024
- Japan mulls ways to boost cell, gene therapy approvals - BioWorld Online - October 22nd, 2024
- A New Type of Gene Therapy Shows Promise for Treating Retinitis Pigmentosa - Managed Healthcare Executive - October 22nd, 2024
- Buy, Sell, Hold: Cell and Gene Therapy - Part 2 - BioPharm International - October 22nd, 2024
- When a Miracle Cure Is Left on the Shelf - Bloomberg - October 22nd, 2024
- Genethon to Showcase the Latest Advances in Gene Therapies for Multiple Diseases at the ESGCT 31 - Business Wire - October 22nd, 2024
- MeiraGTx's gene therapy improves motor function and quality of life in phase 2 Parkinson's trial - Fierce Biotech - October 22nd, 2024
- 5 Sickle Cell Therapies to Watch Following Pfizers Oxbryta Exit - BioSpace - October 22nd, 2024
- Fiocruz and GEMMABio announce partnership for the development of gene therapies - Fiocruz - October 22nd, 2024
- JPMA on Japans Biotech Industry: Cancer, Cardiovascular, and Aging Lead Diseases; Antibody, Cell, and Gene Therapies Top the Innovation List -... - October 22nd, 2024
- Cell and Gene Therapy Clinical Trial Market is expected to reach USD 119.3 Billion by 2032 at a 24.9% of CAGR - PharmiWeb.com - October 22nd, 2024
- Buy, Sell, Hold: Cell and Gene Therapy - Part 3 - Pharmaceutical Technology Magazine - October 22nd, 2024
- The role of quality assurance in accelerating drug development for emerging therapies - pharmaphorum - October 22nd, 2024
- Cellectis to Present Data on TALE-Base Editors and Non-Viral Gene Therapy at the ESGCT 31st Annual Congress - The Manila Times - October 22nd, 2024
- Nucleic Acid and Gene Therapies in Neuromuscular Disorders Market is projected to grow at a CAGR of - PharmiWeb.com - October 22nd, 2024
- Gene therapy: advances, challenges and perspectives - PMC - October 6th, 2024
- Meeting on the Mesa to Highlight Cell and Gene Therapy Opportunities, Challenges - BioSpace - October 6th, 2024
- Ferring opens doors to Finnish manufacturing hub as supply of its bladder cancer gene therapy continues to grow - FiercePharma - October 6th, 2024
- Meet Boston's National STEM Champion who's a junior in high school studying gene therapy - CBS Boston - October 6th, 2024
- Gene therapy research offers hope for kids with life-altering condition - WCVB Boston - October 6th, 2024
- Is gene therapy the next big step in vision loss treatment? - Medical News Today - October 6th, 2024
- Protein's Role in Insulin Signaling Could Have Implications for Gene Therapy - AJMC.com Managed Markets Network - October 6th, 2024
- Scientists overcome major challenge in gene therapy and drug delivery - News-Medical.Net - October 6th, 2024
- Innovative gene therapy for hemophilia - healthcare-in-europe.com - October 6th, 2024
- The Largest Network of Research Sites Vetted to Execute Complexities of Cell & Gene Therapy (CGT) Trials Now Includes 1,500 Sites - PR Newswire - October 6th, 2024
- Weight loss drug breakthroughs, gene therapies, and more: 8 clinical trials to watch right now - Quartz - October 6th, 2024
- Cell therapy weekly: Promising Phase I results for Parkinsons disease cell therapy - RegMedNet - October 6th, 2024
- Targeting CREB-binding protein (CBP) abrogates colorectal cancer stemness through epigenetic regulation of C-MYC - Nature.com - October 6th, 2024
- Forge Biologics Announces the FUEL AAV Manufacturing Platform to Provide Developers with a More Efficient Solution for Gene Therapy Production -... - October 6th, 2024
- Ninth Circuit Decision Marks Critical Legal Victory for U.S. FDA in Mission to Protect Patients from Unregulated Cell Therapy Products - PR Newswire - October 6th, 2024
- Gene therapy: What is it and how does it work? | Live Science - September 21st, 2024
- How Does Gene Therapy Work? Types, Uses, Safety - Healthline - September 21st, 2024
- In race to make gene therapy for age-related blindness, 4D Molecular announces positive results - STAT - September 21st, 2024
- Penn gene therapy pioneer Jim Wilson explains why he's leaving - The Business Journals - September 21st, 2024
- Whats the Meaning of Cure in Gene Therapy? - Managed Healthcare Executive - September 21st, 2024
- Ori doubles down on Charles River collaboration with promising new data on its automated cell therapy platform - FiercePharma - September 21st, 2024
- Doctors cured her sickle-cell disease. So why is she still in pain? - Nature.com - September 21st, 2024
- Gene Therapy Company Increases Focus on Mesothelioma Program - Mesothelioma.net Blog - September 21st, 2024
- Sickle cell gene therapies roll out slowly : Shots - Health News - NPR - September 21st, 2024
- Patients At Last Begin Receiving Vertex-CRISPR and Bluebird Sickle Cell Gene Therapies - BioSpace - September 21st, 2024
- Beacon Therapeutics Presents 36-Month Interim Results from Phase I/2 HORIZON Trial of AGTC-501 in Patients with XLRP - PR Newswire - September 21st, 2024
- Beacons Gene Therapy Shows Continued Promise in Trial - TipRanks - September 21st, 2024
- How stem cell and gene therapies are revolutionising healthcare - Express Healthcare - September 21st, 2024
- Nanoscope Therapeutics to be Featured at Annual EUretina Congress in Barcelona - PR Newswire - September 21st, 2024
- 6-year-old Tennessee boy denied potentially life-saving gene therapy by insurance company - WCYB - September 21st, 2024
- Seeking a sickle cell cure: 12-year-old in DC is 1st patient in US to get new gene therapy - NBC Washington - May 24th, 2024
- Game-changer: The Hindu Editorial on approval for gene therapy to treat sickle cell disease and beta thalassemia - The Hindu - December 13th, 2023
- Early trials show promise for innovative gene therapy in lung cancer treatment - WJAR - October 16th, 2023
- Cell and Gene Therapy Manufacturing Quality Control Market Growing Trends and Technology Forecast to 2029 |... - SeeDance News - October 16th, 2023
- How Gene Therapy Can Cure or Treat Diseases | FDA - March 21st, 2023
- Genetic Therapies - What Are Genetic Therapies? | NHLBI, NIH - March 21st, 2023
- FDA approves novel gene therapy to treat patients with a rare form of ... - December 28th, 2022
- Gene Therapy - Discover How It Works Its Types And Applications - BYJUS - December 28th, 2022
- IVERIC bio Subsidiary Sells Assets of Gene Therapy Product Candidates for Treatment of Retinal Diseases - Marketscreener.com - December 28th, 2022
- Mustang Bio Announces Phase 1/2 Clinical Trial Data of MB-106, a First-in-Class CD20-targeted, Autologous CAR T Cell Therapy, to be Presented at 11th... - October 31st, 2022